Grifols (GIFLF) Goodwill & Intangibles (2010 - 2025)
Grifols (GIFLF) reported Goodwill & Intangibles of $11.1 billion for Q4 2025, up 0.83% on a YoY basis from $11.0 billion in Q4 2024, and up 0.83% quarter-over-quarter from $11.0 billion in Q4 2024.
Grifols (GIFLF) Goodwill & Intangibles (2010 - 2025) Analysis & Trends
Grifols has reported Goodwill & Intangibles for 16 years, with the latest figure at $11.1 billion in Q4 2025.
- For the quarter ending Q4 2025, Goodwill & Intangibles rose 0.83% year-over-year to $11.1 billion; the trailing twelve-month figure through Dec 2025 stood at $11.1 billion (up 0.83% YoY), and the FY2025 full-year result was $11.1 billion, up 0.83% from the prior year.
- Goodwill & Intangibles for Q4 2025 stood at $11.1 billion, up from $11.0 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $11.1 billion in Q4 2025, with the low at $7.4 billion in Q4 2023.
- Historically, Goodwill & Intangibles has averaged $9.8 billion across 5 years, with a median of $10.2 billion in 2022.
- Annual changes were most pronounced in 2023 — Goodwill & Intangibles fell 26.75% — and 2024, when it soared 48.27%.
- Grifols' Goodwill & Intangibles stood at $9.0 billion in 2021, then grew by 12.94% to $10.2 billion in 2022, then slipped by 26.75% to $7.4 billion in 2023, then soared by 48.27% to $11.0 billion in 2024, then rose by 0.83% to $11.1 billion in 2025.
- The last three Goodwill & Intangibles figures came in at $11.1 billion (Q4 2025), $11.0 billion (Q4 2024), and $7.4 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.13 Bn |
| Dec 31, 2024 | 11.04 Bn |
| Dec 31, 2023 | 7.44 Bn |
| Dec 31, 2022 | 10.16 Bn |
| Dec 31, 2021 | 9.00 Bn |
| Dec 31, 2020 | 8.21 Bn |
| Sep 30, 2020 | 8.95 Bn |
| Mar 31, 2020 | 8.61 Bn |
| Dec 31, 2019 | 8.46 Bn |
| Sep 30, 2019 | 8.77 Bn |
| Mar 31, 2019 | 8.43 Bn |
| Dec 31, 2018 | 7.53 Bn |
| Sep 30, 2018 | 7.65 Bn |
| Jun 30, 2018 | 7.56 Bn |
| Mar 31, 2018 | 7.11 Bn |
| Dec 31, 2017 | 6.90 Bn |
| Jun 30, 2017 | 5.55 Bn |
| Dec 31, 2016 | 5.23 Bn |
| Sep 30, 2016 | 3.81 Bn |
| Jun 30, 2016 | 3.94 Bn |